ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1090

A Multidisciplinary Performance Improvement Approach to Achieving Goal Serum Uric Acid Levels in Patients with Gout

Luke Monteagudo1, Jefferson Roberts2, Donna Kido3, Collette Chin3 and Susan Fujii3, 1Internal Medicine, Tripler Army Medical Center, Honolulu, HI, 2Rheumatology, Tripler Army Medical Center, Honolulu, HI, 3Pharmacy, Tripler Army Medical Center, Honolulu, HI

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: gout, performance and pharmacists

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Measures and Measurement of Healthcare Quality Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: In patients with gout, hyperuricemia leads to inflammation induced by mono-sodium urate crystal deposition. This causes irreversible physical and radiographically evident destruction of the affected joint. Current guidelines recommend a serum uric acid (sUA) level < 6 mg/dL, while data has shown that sUA of < 5 mg/dL has benefit. The aim of this performance improvement project was to assess how to better achieve these goals. We hypothesized that through a multidisciplinary approach, we could more effectively achieve sUA goal levels.

Methods: We enrolled patients with a new or chronic diagnosis of gout. We excluded pregnant women and those under the age of 18. Baseline sUA levels were obtained on all patients. If elevated and not already on urate lowering therapy, patients were started on 100mg Allopurinol daily and 0.6mg Colchicine twice daily. A clinical pharmacist followed our algorithm for a step wise increase in therapy intensity every two weeks, with a corresponding sUA level.

Results: A total of 40 patients participated. The average starting uric acid level of the experimental group was 8.06 mg/dL. After 12 months, 48% (n=19) of patients reached a level below 6 mg/dL. After an average of 18.5 months of enrollment, 33% of patients (n=13) reached a serum uric acid level below 5 mg/dL and 53% (n=21) reached a serum uric acid level below 6 mg/dL.

Conclusion: The aim of our approach to gout treatment is to decrease sUA, gout attacks, and ultimately joint damage. We were able to show that a multidisciplinary approach could improve sUA level compared with primary physicians alone. This effect is due to clinical pharmacists’ ability to perform more frequent sUA evaluations and medication changes for patients. Future work will evaluate secondary end points, like the number of acute care visits and gout attacks during the study period. The summation of this data supports the multidisciplinary approach to the treatment of gout.


Disclosure: L. Monteagudo, None; J. Roberts, None; D. Kido, None; C. Chin, None; S. Fujii, None.

To cite this abstract in AMA style:

Monteagudo L, Roberts J, Kido D, Chin C, Fujii S. A Multidisciplinary Performance Improvement Approach to Achieving Goal Serum Uric Acid Levels in Patients with Gout [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/a-multidisciplinary-performance-improvement-approach-to-achieving-goal-serum-uric-acid-levels-in-patients-with-gout/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-multidisciplinary-performance-improvement-approach-to-achieving-goal-serum-uric-acid-levels-in-patients-with-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology